Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

Original reporting
Published Nov 12, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGEN
Bullish
high confidence
Mentioned
$CGEN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGENBullishMed
01

Why it matters

The analyst's reiteration of a Buy rating and a $4 target, combined with trial enrollment progress, creates a bullish catalyst for the stock.

02

Market read

The article provides fresh analyst coverage and trial enrollment data, offering a medium‑term upside thesis for CGEN.

03

What to watch

Potential delays in trial readout and reliance on partnership payments for cash flow.

Relevance 7/10Novelty 7/10Timing: today

Background

Compugen (NASDAQ:CGEN) is a clinical‑stage biotech focused on immune‑checkpoint therapies. The MAIA‑ovarian study evaluates COM701 in relapsed ovarian cancer.

Company-level read

Ticker impact

$CGENBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating with a $4 price target after Compugen's Q3 results and enrollment update for its MAIA-ovarian trial.

Expected impact

likely upward pressure as the market prices in the $4 target versus current $2.09 price

Evidence & confidence

The buy rating and target provide a clear actionable catalyst; trial enrollment indicates future revenue upside.

Market effects

Positive signal for clinical‑stage biotech sector as trial progress may boost peer valuations.

Limited to US biotech investors.

Modest; primarily affects investors tracking small‑cap biotech stocks.

Counterpoint

The revenue miss and lack of EPS guidance could temper enthusiasm despite the upgrade.

Key entities

  • Compugen

    Clinical‑stage biotech developing COM701.

  • H.C. Wainwright

    Equity research firm issuing the Buy rating.

Related articles

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.

$NVDAHighAI 9/10

Nvidia earnings beat lifts Bitcoin mining stocks

Nvidia (NVDA) reported Q3 2026 earnings, beating estimates with $2.68 EPS and $115.8B revenue. Data center revenue rose 110% YoY. Q4 outlook is $127.4B-$132.6B, above analyst estimates. Bitcoin mining stocks like MARA, HUT, RIOT, IREN, and CRWV rose, as some pivot to AI due to rising mining costs and Bitcoin's price drop.